Apogee Therapeutics (APGE) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
9 Jun, 2026Opening remarks and agenda
Meeting opened with introductions of the board, executive team, and external auditors.
Agenda included business items, voting, and a Q&A session for shareholders.
Board and executive committee updates
Board members and executive officers were introduced, including new and continuing directors.
Shareholder proposals
Three proposals were presented: election of Class III directors, ratification of the auditor, and advisory approval of executive compensation.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Apogee Therapeutics
- Zumi shows strong efficacy and flexible dosing, supporting expansion and commercialization plans.APGE
Goldman Sachs 47th Annual Global Healthcare Conference 202610 Jun 2026 - Strong phase II-B results and a $1.3B Blackstone deal drive late-stage and combo program expansion.APGEJefferies Global Healthcare Conference 20263 Jun 2026
- Mid-dose zumilokibart achieved 65.9% EASI-75 at 16 weeks with strong safety and $1.3B funding.APGEStudy result30 May 2026
- Durable AD efficacy, $1.3B cash, and Phase 3 plans highlight strong Q1 2026 progress.APGEQ1 202611 May 2026
- Proxy covers director elections, auditor ratification, say-on-pay, and strong governance practices.APGEProxy filing24 Apr 2026
- Shareholders to elect directors, approve executive pay, and ratify auditor at virtual meeting.APGEProxy filing24 Apr 2026
- Sustained, deepening efficacy and safety achieved with infrequent dosing over 52 weeks.APGEStudy result23 Mar 2026
- Quarterly and semi-annual dosing data for atopic dermatitis expected soon, with phase 3 launch this year.APGETD Cowen 46th Annual Health Care Conference3 Mar 2026
- Zumilokibart targets best-in-class efficacy and dosing in AD, with pivotal data expected in 2026.APGECorporate presentation3 Mar 2026